Previous 10 | Next 10 |
home / stock / fh:cc / fh:cc news
Filament Health and Jaguar Health Sign Letter of Intent to Develop Botanical Prescription Drugs for Specific Mental Health Indications Canada NewsWire Drug discovery collaboration will leverage the botanical drug development expertise of both companies VANCOU...
FILAMENT HEALTH IS ISSUED SECOND PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE AND REPORTS Q1 RESULTS Canada NewsWire The patent describes the extraction and standardization of stable doses of psychedelic compounds The Company also reports first quarter 2...
FILAMENT HEALTH ANNOUNCES FOURTH PATENT ISSUANCE Canada NewsWire The patent describes the extraction and standardization of stable doses of psychedelic compounds VANCOUVER, BC , April 27, 2022 /CNW/ - Filament Health Corp. (OTCQB:FLHLF) (N...
VANCOUVER, British Columbia, April 25, 2022 (GLOBE NEWSWIRE) -- Filament Health (OTCQB:FLHLF) (NEO:FH) (FSE:7QS), a clinical-stage natural psychedelic drug development company, today announced that Benjamin Lightburn, CEO and Co-Founder, will present live at VirtualInvestorConferen...
VANCOUVER, BC / ACCESSWIRE / April 19, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Hank Payments, Red Pine Exploration, Affinor Growers, Nextech AR, Star Navigation, and Psyence on their latest news. The Power Play by The Market Herald provide...
FILAMENT HEALTH AND PSYENCE ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR NATURAL PSILOCYBIN PRODUCTS Canada NewsWire The partnership leverages Psyence's expertise in fungi cultivation and palliative care as well as Filament's expertise in the manufacture of pharmaceuti...
VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc ( CSE: PSYG | OTCQB: PSYGF ) (“Psyence”), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, and Fila...
FILAMENT HEALTH IS ISSUED PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE Canada NewsWire The patent describes the extraction and standardization of stable doses of psychedelic compounds VANCOUVER, BC , April 13 , 2022 /CNW/ - Filament Hea...
FILAMENT HEALTH ANNOUNCES PRE-IND MEETING WITH UNITED STATES FOOD AND DRUG ADMINISTRATION Canada NewsWire VANCOUVER, BC , April 12, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinica...
FILAMENT HEALTH TO PARTICIPATE IN PROMINENT PSYCHEDELIC INVESTOR CONFERENCES IN APRIL 2022 Canada NewsWire VANCOUVER, BC , April 7, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage ...
News, Short Squeeze, Breakout and More Instantly...
FILAMENT HEALTH CORP. Company Name:
FH:CC Stock Symbol:
AQNC Market:
FILAMENT HEALTH ANNOUNCES CLOSING OF WARRANT EXERCISE, NOTE CONVERSION AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES Canada NewsWire VANCOUVER, BC , June 12, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (" Filament " ...
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER Canada NewsWire Company study investigating PEX010, Filament's botanical psilocybin drug candidate, has been authorized by both FDA and Health Canada...
FILAMENT HEALTH ANNOUNCES WARRANT EXERCISE AND NOTE CONVERSION BY NEGEV CAPITAL AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES TO BENJAMIN LIGHTBURN, CHIEF EXECUTIVE OFFICER Canada NewsWire VANCOUVER, BC , June 3, 2024 /CNW/ - Filament Health Corp. (OTCQB:...